MT1G and nonpapillary renal cell carcinoma: In ccRCC, the relative upregulation of MT1G may lead to tumor progression to the advanced stage and resistance to sorafenib, which might contribute to the effect of MT1G on ferroptosis by regulating GSH consumption.